---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-206398"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:30:23.913927+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Q1 2026 net loss $73.3M; FDA BTD for zovegalisib; cash $642M

## Summary
- FDA granted Breakthrough Therapy designation to zovegalisib+fulvestrant for PIK3CA-mutant HR+/HER2- advanced breast cancer.
- Median PFS 11.1 months in heavily pre-treated patients; similar efficacy across kinase and non-kinase mutations.
- Phase 3 1L trial of zovegalisib+atirmociclib expected early 2027; Pfizer to supply atirmociclib.
- Initiated Phase 1/2 trial of RLY-8161, an NRAS-selective inhibitor, in NRAS-mutant solid tumors.
- Cash, cash equivalents and investments $642.1M; net loss $73.3M ($0.41 per share) for Q1 2026.

## SEC filing metadata
- accession: 0001193125-26-206398
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000119312526206398/0001193125-26-206398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000119312526206398/rlay-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-206398
- JSON: https://secwatch.observer/filing/0001193125-26-206398.json
- Plain text: https://secwatch.observer/filing/0001193125-26-206398.txt

## Key facts
- Earnings Releases
  Relay Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue 3.0, net income -73.3, EPS -0.41.
  - Period: first quarter ended March 31, 2026
  - Revenue: 3.0
  - Net income: -73.3
  - EPS: -0.41
  - Result: reported results
  source text: --- EX-99.1 Exhibit 99.1 Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doublet data at Phase 3 dose in CDK4/6-experienced
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812364/000119312526206398/0001193125-26-206398-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.